The use of systemic antibiotics in the treatment of chronic wounds

Dermatologic Therapy

Volumn 19, Issue 6, 2006, Pages 326-337

  Hernandez, Robert ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Antibiotics; Chronic; Infection; Systemic; Wounds

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFALEXIN; CEFIXIME; CEFOTAXIME; CEFPODOXIME PROXETIL; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METRONIDAZOLE; NAFCILLIN; OFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; UNINDEXED DRUG; VANCOMYCIN;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTERIUM; CELLULITIS; CHRONIC WOUND; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; CROSS ALLERGY; DIABETES MELLITUS; DIAGNOSTIC TEST; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INTERACTION; EXFOLIATIVE DERMATITIS; GERIATRIC PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; INJECTION SITE IRRITATION; KIDNEY FAILURE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OSTEOMYELITIS; OTOTOXICITY; PAPULE; PENICILLIN ALLERGY; PRURITUS; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STEVENS JOHNSON SYNDROME; SYSTEMIC THERAPY; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; URTICARIA; VOMITING; WOUND ASSESSMENT; WOUND INFECTION;

EID: 33845668361     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2006.00091.x     Document Type: Review

References (48)

1. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Reg 2003: 11: S1-S28.
2. Frantz RA. Identifying infection in chronic wounds. Nursing 2005: 35: 73.
3. Gardner SE, Frantz RA, Doebbeling BN. The validity of the clinical signs and symptoms used to identify localized chronic wound infection. Wound Repair Regen 2001: 9: 178-186.
4. Edwards R, Harding KG. Bacteria and wound healing. Curr Opin Infect Dis 2004: 17: 91-96.
5. Pollack SV. The wound healing process. Clin Dermatol 1984: 2: 8-16.
6. Robson MC. Wound infection. A failure of wound healing caused by an imbalance of bacteria. Wound Healing. Surg Clin North Am 1997: 77: 637-650.
7. Mertz PM. Cutaneous biofilms: friend or foe? Wounds 2003: 15: 129-132.
8. Polonio RE, Mermel LA, Paquette GE, Sperry JF. Eradication of biofilm-forming Staphylococcus epidermidis (rp62a) by a combination of sodium salicylate and vancomycin. Antimicrob Agents Chemother 2001: 45: 3262-3266.
9. Ceri H, Olsen ME, Stremick C, et al. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1996: 37: 1771-1776.
10. Mertz PM, Ovington LG. Wound healing microbiology. Wound healing. Dermatol Clin 1993: 11: 739-747.
11. Neidner Schopf E. Wound infections and antibacterial therapy. In: Westerhof W, ed. Leg ulcers: diagnosis and treatment. New York: Elsevier Science Publishers, 1993: 293-303.
12. McGukin M, Goldman R, Bolton L, Salcido R. The clinical relevance of microbiology in acute and chronic wounds. Skin Wound Care 2003: 16: 12-23.
13. Craig WA, Andes DR. Parenteral versus oral antibiotic therapy I. Med Clin N Am 1995: 79: 497-509.
14. Craig WA. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microbiol 1993: 12 (Suppl. 1): S6.
15. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1990: 74 (Suppl. 5A): 63-70.
16. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993: 37: 1073-1081.
17. Lettieri T, Rogge MC, Kaiser L, et al. Pharmacokinetic pro-files of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992: 36: 993-996.
18. Janknegt R, van der Meer JWM. Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994: 33: 169-177.
19. Norrby R. Linezolid - a review of the first oxazolidinone. Expert Opin Pharmacother 2001: 2: 293-302.
20. Gentry LO, Ramirez-Ronda CH, Rodriguez-Noriega E, et al. Oral ciprofloxacin vs. parenteral cefotaxime in the treatment of difficult skin and skin structure infections. A multicenter trial. Arch Intern Med 1989: 149: 2579-2583.
21. Gentry LO, Rodriguez-Gomez G, Zeluff BJ, et al. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am J Med 1989: 87 (Suppl. 6C): 57S-60S.
22. Gentry LO, Koshdel A. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure. Am J Med 1989: 87 (Suppl. 5A): 132S-135S.
23. Del Rosal PL, Del Rosal LL, Riosvelasco CA, et al. Brief report: prospective, controlled, randomized, non-blind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of severe surgical infections. Am J Med 1989: Suppl 5A: 183S-184S.
24. Cunha BA. Intravenous-to-oral antibiotic switch therapy. A cost-effective approach. Postgrad Med 1997: 101: 111-116.
25. Bowler PG. Wound pathophysiology, infection and therapeutic options. Ann Med 2002: 34: 419-427.
26. Davies CE, Wilson MJ, Hill KE, et al. Use of molecular techniques to study microbial diversity in the skin: chronic wounds reevaluated. Rep Reg 2001: 9: 332-340.
27. Bowler PG, Davies BJ. The microbiology of acute and chronic wounds. Wounds 1999: 11: 72-78.
28. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issues October 2004. Am J Infect Control 2004: 32: 470-485.
29. Namias N, Samiian L, Nino D, et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 2000: 49: 638-645.
30. Centers for Disease Control. Outbreak of community-associated methicillin-resistant Staphylococcus aureus skin infections - Los Angeles County, California, 2002-2003. Morb Mortal Wkly Rep 2003: 52: 88.
31. Centers for Disease Control. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. Morb Mortal Wkly Rep 2003: 52: 793-795.
32. Centers for Disease Control. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison - Mississippi, 2000. Morb Mortal Wkly Rep 2001: 50: 919-922.
33. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003: 290: 2976-2984.
34. Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html
35. Weigelt J, Itani K, Stevens D, et al. Linezolid CSSTI Study Group. Linezolid versus vancomycin in the treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005: 49: 2260-2266.
36. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004: 38: 1673-1681.
37. Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000: 46: 775-784.
38. Shittu A, Lin J. Newer anti-staphylococcal agents: in vitro studies and emerging trends in Staphylococcus aureus resistance. Wounds 2006: 18: 129-146.
39. Salkind AR, Cuddy PG, Foxworth JW. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA 2001: 285: 2498-2505.
40. Arroliga ME, Wagner W, Bobek MB, et al. A pilot study of penicillin skin testing in patients with a history of penicillin allergy admitted to a medical ICU. Chest 2000: 118: 1106-1108.
41. Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med 2001: 345: 804-809.
42. Saxon A, Adelman DC, Patel A, et al. Imipenem crossreactivity with penicillin in humans. J Allergy Clin Immunol 1988: 82: 213-217.
43. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005: 366: 1736-1743.
44. Louie TJ, Bartlett JG, Tally FP, Gorbach SL. Aerobic and anaerobic bacteria in diabetic foot ulcers. Ann Intern Med 1976: 85: 461-463.
45. Hughes TH. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990: 161: 381-396.
46. Giamerelou H. Empiric therapy for infections in the febrile, neutropenic, compromised host. Med Clin North Am 1995: 79: 559-576.
47. Billote KP, Mendoze M, Baylon HG. Infections in febrile neutropenia and possible prognostic factors associated with mortality. Phil J Microbiol Infect Dis 1997: 26: 55-59.
48. Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. The Sanford guide to antimicrobial therapy. 35th ed. Hyde Park, VT: Antimicrobial Therapy, Inc, 2005.